GCAN Greater Cannabis Company Inc (PK)

GammaCan International, Inc.(OTC BB: GCAN) today announced the appointment of Lynn Schuchter M.D. to the Company�s Scientific Advisory Board. Dr. Schuchter, an oncologist whose research and clinical work is focused on melanoma and breast cancer. Dr. Schuchter is also the Program Leader of the Clinical Investigations Program at the Abramson Cancer Center of the University of Pennsylvania. �We are extremely pleased that Lynn has joined our Scientific Advisory Board. Lynn�s involvement in the development of innovative approaches to melanoma therapy provides a perfect fit with our goals to develop VitiGam to treat stage III and IV melanoma. The entire Team at GammaCan is looking forward to working with Lynn and warmly welcomes her�, stated Patrick Schnegelsberg, CEO. About VitiGam: VitiGam is GammaCan's second generation intravenous IgG-based product and a first-in-class anti-cancer immunotherapy. GammaCan plans on having VitiGam enter phase I/II testing under a US IND in the near future after recently holding a pre-IND meeting with the FDA. VitiGam is being designed to target metastatic melanoma patients with Stage III and IV melanoma. VitiGam is an IgG product that is different from standard IgGs: It is manufactured from the plasma of donors with vitiligo, a benign autoimmune skin condition affecting up to 2% of the general population. GammaCan scientists have shown that this "enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma activity in both in vitro and mouse xenograft melanoma models. Thus, GammaCan expects VitiGam to provide (1) anti-melanoma activity directed specifically against malignant melanoma cells and (2) non-specific anti-cancer activity - as is the case with IgG in general. About GammaCan GammaCan is focusing on the commercialization of an innovative anti-cancer immunotherapy to treat metastatic cancer. GammaCan's platform is based on IVIg, a safe, relatively non-toxic human plasma-based product, currently used to treat a variety of immune deficiencies and autoimmune diseases. IVIg works by strengthening the patient's immune system. Many experts currently view immunotherapy as a future alternative to today's standard chemotherapy. GammaCan is developing VitiGam, its second generation program. VitiGam is an IVIg derived from the plasma of vitiligo donors and is being developed to treat malignant melanoma. GammaCan owns, and has applied for US patent protection covering the use of IVIg and vitiligo-derived IVIg (VitiGam). For more information about GammaCan visit www.GammaCan.com or call the company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616 or toll free 1-866-308-0396 (from North America). Safe Harbor Statement: Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding the commercialization of an anti-cancer immunotherapy and the Company developing the boosting of cancer patients' immune systems with IVIg into an effective treatment. Actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology, unforeseen technical difficulties in developing the technology, the inability to obtain regulatory approval for human use, competitors' therapies proving more effective, cheaper or otherwise preferable for consumers, inability to market the product we produce, among other factors, all of which could among other things, delay or prevent product release or cause our company to fail. For further risk factors see the risk factors associated with other early state medical research and development companies filed with the SEC on Edgar. GammaCan International, Inc.(OTC BB: GCAN) today announced the appointment of Lynn Schuchter M.D. to the Company's Scientific Advisory Board. Dr. Schuchter, an oncologist whose research and clinical work is focused on melanoma and breast cancer. Dr. Schuchter is also the Program Leader of the Clinical Investigations Program at the Abramson Cancer Center of the University of Pennsylvania. "We are extremely pleased that Lynn has joined our Scientific Advisory Board. Lynn's involvement in the development of innovative approaches to melanoma therapy provides a perfect fit with our goals to develop VitiGam to treat stage III and IV melanoma. The entire Team at GammaCan is looking forward to working with Lynn and warmly welcomes her", stated Patrick Schnegelsberg, CEO. About VitiGam: VitiGam is GammaCan's second generation intravenous IgG-based product and a first-in-class anti-cancer immunotherapy. GammaCan plans on having VitiGam enter phase I/II testing under a US IND in the near future after recently holding a pre-IND meeting with the FDA. VitiGam is being designed to target metastatic melanoma patients with Stage III and IV melanoma. VitiGam is an IgG product that is different from standard IgGs: It is manufactured from the plasma of donors with vitiligo, a benign autoimmune skin condition affecting up to 2% of the general population. GammaCan scientists have shown that this "enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma activity in both in vitro and mouse xenograft melanoma models. Thus, GammaCan expects VitiGam to provide (1) anti-melanoma activity directed specifically against malignant melanoma cells and (2) non-specific anti-cancer activity - as is the case with IgG in general. About GammaCan GammaCan is focusing on the commercialization of an innovative anti-cancer immunotherapy to treat metastatic cancer. GammaCan's platform is based on IVIg, a safe, relatively non-toxic human plasma-based product, currently used to treat a variety of immune deficiencies and autoimmune diseases. IVIg works by strengthening the patient's immune system. Many experts currently view immunotherapy as a future alternative to today's standard chemotherapy. GammaCan is developing VitiGam, its second generation program. VitiGam is an IVIg derived from the plasma of vitiligo donors and is being developed to treat malignant melanoma. GammaCan owns, and has applied for US patent protection covering the use of IVIg and vitiligo-derived IVIg (VitiGam). For more information about GammaCan visit www.GammaCan.com or call the company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616 or toll free 1-866-308-0396 (from North America). Safe Harbor Statement: Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding the commercialization of an anti-cancer immunotherapy and the Company developing the boosting of cancer patients' immune systems with IVIg into an effective treatment. Actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology, unforeseen technical difficulties in developing the technology, the inability to obtain regulatory approval for human use, competitors' therapies proving more effective, cheaper or otherwise preferable for consumers, inability to market the product we produce, among other factors, all of which could among other things, delay or prevent product release or cause our company to fail. For further risk factors see the risk factors associated with other early state medical research and development companies filed with the SEC on Edgar.